“…Their strategy, using iPSDCs, may overcome the issues how to obtain sufficient numbers and the good condition of the vaccine components. Vaccine therapy using genetically modified iPSDCs expressing CEA is a promising clinical application for the treatment of gastrointestinal cancer [1] , in which microbiota may lead to excellent possibilities of discovering novel strategies for more effective cancer treatments [4] .…”